Obtenga las últimas noticias sobre las acciones de Passage Bio con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de PASG

Últimas noticias sobre

PASSAGE BIO INC

Passage Bio

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

Passage Bio Inc

News

Press Releases

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

Earnings

Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

Health Care

General

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

Markets

Passage Bio Announces 1-for-20 Reverse Stock Split

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

PASG

Abpro Hldgs

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

BioAtla

Boundless Bio

Curis

Enlivex Therapeutics Ltd. - Ordinary Shares

Enlivex Therapeutics

Evaxion

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

FibroBiologics

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Geovax Labs

Kairos Pharma

Lisata Therapeutics

Nanoviricides

OSR Holdings

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Portage Biotech

Q32 Bio

Rallybio

Rein Therapeutics

SAB Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

TAO Synergies

Tenax Therapeutics

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Royalty

Canaccord Genuity

Guggenheim

Wedbush

Chardan Capital

Rodman & Renshaw

Comments

Passage Bio Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL